Disputes have erupted among attorneys representing a class of buyers in an antitrust case against pharmaceutical giant Pfizer pertaining to the cholesterol medication Lipitor. The issue at hand revolves around the disbursement of attorney fees, estimated up to $31 million. This disagreement has unfolded even before the total sum has been officially approved by a federal judge in New Jersey.
The documentations before the court have shed some light on this internal tussle among the legal representatives for the class of buyers. These documents add a key dimension to what has been a more publicly planet-wide $93 million antitrust settlement against Pfizer, directly involving consumers of Lipitor.
Pfizer’s Lipitor has been in the center of antitrust litigation, effectively drawing on the contention around brand names and generic entries in the pharmaceutical market. The moot point in question lies in Pfizer’s conduct with respect to facilitating or inhibiting the market entry of generic versions of the medication, primarily post the expiration of the drug’s patent.
Legal experts and industry observers are closely following this contentious distribution of attorney fees, often seen as a murky area of class-action lawsuits. The implications of this case may be far-reaching, not just for the lawyers involved but also for the wider landscape of antitrust lawsuits and settlements.
For a more extensive exploration of the details of the litigation and fee dispute, you can visit the Law360 article here.